Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCZ known ✓ | Q05513 | 1/20 | 0.32 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.31 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.31 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.31 |
| ▸ | FLT3 known ✓ | P36888 | 3/20 | 0.31 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 0.31 |
| ▸ | KDR known ✓ | P35968 | 2/20 | 0.31 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.30 |
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.30 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.30 |
| ▸ | NTRK1 known ✓ | P04629 | 1/20 | 0.30 |
| ▸ | RET known ✓ | P07949 | 1/20 | 0.30 |
| ▸ | MET known ✓ | P08581 | 1/20 | 0.30 |
| ▸ | NTRK2 known ✓ | Q16620 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28663126 | 1.00 | ALDH1A1 (0.43) | ALDH1A1CYP3A4TDP1TP53HSD17B10 | |
| Hydrochloric Acid SCHEMBL28335260 | 1.00 | ALDH1A1 (0.43) | ALDH1A1CYP3A4TDP1TP53HSD17B10 | |
| Hydrochloric Acid SCHEMBL992776 | 0.98 | CYP3A4 (0.46) | ALDH1A1CYP3A4TDP1TP53HSD17B10 | |
| Water SCHEMBL7066183 | 0.98 | TDP1 (0.46) | ALDH1A1CYP3A4TDP1TP53HSD17B10 | |
| Hydrochloric Acid SCHEMBL999548 | 0.98 | CYP3A4 (0.46) | ALDH1A1CYP3A4TDP1TP53HSD17B10 | |
| Hydrochloric Acid SCHEMBL134929 | 0.98 | CYP3A4 (0.46) | ALDH1A1CYP3A4TDP1TP53HSD17B10 | |
| SCHEMBL21373 | 0.95 | TDP1 (0.48) | ALDH1A1CYP3A4TDP1TP53HSD17B10 | |
| SCHEMBL5983370 | 0.95 | TDP1 (0.48) | ALDH1A1CYP3A4TDP1TP53HSD17B10 | |
| SCHEMBL30272720 | 0.95 | TDP1 (0.48) | ALDH1A1CYP3A4TDP1TP53HSD17B10 | |
| SCHEMBL3507048 | 0.93 | TDP1 (0.46) | ALDH1A1CYP3A4TDP1TP53HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4816387-A | ELECTROPHORESIS, COLORIMETRIC ANALYSIS | BIO-RESEARCH LABORATORIES, INC. (US) | 1989-03-28 | — | — | US | claimed |
| WO-1987007647-A1 | METHOD FOR DETECTION OF ANTIBODIES TO HTLV-III VIRUS AND DIAGNOSTIC TEST KIT USEFUL THEREWITH | TEXAS BIO-RESEARCH LABORATORIES, INC. (US) | 1987-12-17 | — | — | WO | claimed |
| WO-2023076921-A1 | METHODS FOR ENHANCED BCMA IMMUNOHISTOCHEMISTRY DETECTION IN HUMAN AND MONKEY TISSUE | JANSSEN BIOTECH, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-9097716-B2 | Assay for anti-TR antibodies | ERASMUS UNIVERSITY MEDICAL CENTER (NL) | 2015-08-04 | — | — | US | disclosed |
| US-20150050668-A1 | ASSAY FOR ANTI-TR ANTIBODIES | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2015-02-19 | — | — | US | disclosed |
| US-8883745-B2 | C—glycolipids with enhanced Th-1 profile | NEW YORK UNIVERSITY (US) | 2014-11-11 | — | — | US | disclosed |
| WO-2013129913-A1 | ASSAY FOR ANTI - TR ANTIBODIES | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2013-09-06 | — | — | WO | disclosed |
| CN-101500580-B | C-glycolipids with enhanced Th-1 profile | NEW YORK UNIVERSITY (US) | 2011-12-07 | — | — | CN | disclosed |
| US-20100233207-A1 | C-GLYCOLIPIDS WITH ENHANCED TH-1 PROFILE | NEW YORK UNIVERSITY (US) | 2010-09-16 | — | — | US | disclosed |
| CN-101500580-A | C-glycolipids with enhanced Th-1 profile | UNIV NEW YORK (US) | 2009-08-05 | — | — | CN | disclosed |
| WO-2009040136-A1 | METHODS AND COMPOSITIONS TO TREAT AQUATIC ORGANISMS | GHENT UNIVERSITY (BE) | 2009-04-02 | — | — | WO | disclosed |
| US-5583102-A | ADMINISTERING TO STIMULATE WOUND REGENERATION, DECREASE SCAR FORMATION | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1996-12-10 | — | — | US | disclosed |
| EP-0324834-B1 | METHOD FOR RAPID AND SENSITIVE DETECTION OF HIV-I ANTIBODIES | VERIGEN INC (US) | 1995-11-08 | — | — | EP | disclosed |
| EP-0324834-A4 | METHOD FOR RAPID AND SENSITIVE DETECTION OF HIV-I ANTIBODIES | — | 1992-05-06 | — | — | EP | disclosed |
| US-4885235-A | ELECTROPHORETICALLY RESOLVED HIV-I ANTIGEN IS INCUBATED IN THE PRESENCE OF MILK PROTEIN | 501 BIO-RESEARCH LABORATORIES, INC. (US) | 1989-12-05 | — | — | US | disclosed |
| EP-0324834-A1 | METHOD FOR RAPID AND SENSITIVE DETECTION OF HIV-I ANTIBODIES | VERIGEN, INC. (US) | 1989-07-26 | — | — | EP | disclosed |
| US-4816387-A | ELECTROPHORESIS, COLORIMETRIC ANALYSIS | BIO-RESEARCH LABORATORIES, INC. (US) | 1989-03-28 | — | — | US | disclosed |
| WO-1989000207-A1 | METHOD FOR RAPID AND SENSITIVE DETECTION OF HIV-I ANTIBODIES | BIO RES LAB INC (US) | 1989-01-12 | — | — | WO | disclosed |
| US-4792520-A | Methods and kits for identifying mutagenic agents and molecular mutations in DNA in mammalian cells | UNIVERSITY OF CINCINNATI (US) | 1988-12-20 | — | — | US | disclosed |
| WO-1987007647-A1 | METHOD FOR DETECTION OF ANTIBODIES TO HTLV-III VIRUS AND DIAGNOSTIC TEST KIT USEFUL THEREWITH | TEXAS BIO-RESEARCH LABORATORIES, INC. (US) | 1987-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233207-A1 | C-GLYCOLIPIDS WITH ENHANCED TH-1 PROFILE | ICOS, CD69, TSLP | PRKCZ 2146/4885MAOA 4512/4885MAOB 4346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.